Complement cascade inhibitors, The humanized monoclonal antibody such as Eculizumab, Anti-C5 mAb is used to treat unmanageable CAPS by inhibiting the cleavage of C5 into C5a and C5b and reducing the chemoattractant function [166]. The gene discussed is C5; the disease is cryopyrin-associated periodic syndrome.